Novartis Sandoz Unveils Plan For China Production And Distribution Center
This article was originally published in PharmAsia News
Executive Summary
Novartis Sandoz recently disclosed plans to make its Zhongshan company the China pharmaceutical production base, and will move its current sales center to the city to establish Sandoz China production and distribution center. Set up in Zhongshan in 2007, Novartis Sandoz focuses on pharmaceutical chemicals, capsules, tablets and repackaging of imported medicines. The company's revenue saw more than $40 million in 2008 with its production of eight main types of medicines. Novartis has identified China as the growth engine for its global expansion and top-level corporate executives will visit relevant Chinese government officials by the end of this month. (Click here for more - Chinese Language)
You may also be interested in...
Sandoz Targets RMB 10 Billion China Revenue Within Five Years
During a recent visit to China (PharmaAsia News, Mar. 16, 2009), Sandoz's CEO Jeff George disclosed that global generic drugs will grow annually at 9 percent from 2008 to 2013, while Asia's yearly increase will hit 12 percent. China, spurred by its health care reform, will become the world's second-largest generics market by 2012, with a compound annual growth rate of 14 percent. Eying this opportunity, Sandoz is targeting a revenue of RMB 10 billion for China by 2012, and aims to become among the top three industry manufacturers in the country. The company will accelerate introduction of drugs into China as well as enlarge its operations by M&A or production expansion. (Click here for more - Chinese Language)
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.